3M Company vs GeneDx Holdings Corp — how do they compare? 3M Company trades at $181.89 (market cap $94.44B), while GeneDx Holdings Corp trades at $83.63 (market cap $2.44B). The key difference: 3M Company is far larger — about 38.7× GeneDx Holdings Corp's market cap, and 3M Company pays a 1.7% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MMM | WGS | |
|---|---|---|
Market Cap | $94.44B | $2.44B |
Sector | Industrials | Technology |
52-Week High | $183.13 | $167.51 |
52-Week Low | $141.10 | $34.51 |
Enterprise Value | $103.67B | $2.48B |
Dividend Yield | 1.7% | — |
Signals from Pluang's Aura AI — not financial advice
MMM trades at $182.04, showing modest daily weakness but maintaining a bullish technical trend with strong support near $181. Recent Q2 2026 earnings beat expectations with EPS of $2.40, driven by 5.4% organic growth and margin expansion, leading to raised full-year guidance. The stock's valuation remains elevated with a P/E of 32.53, while analyst sentiment is mixed with a near-even split between buy and hold ratings.
The outlook is cautiously optimistic, supported by operational improvements and innovation in high-growth verticals like Safety & Industrial. Key risks include litigation liabilities and macroeconomic pressures. Upside potential exists if execution continues to surpass expectations, but current prices may already reflect near-term gains.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →